MVA-MUC1-IL2: Updated Phase IIb data

Updated data from a subgroup of 196 NSCLC patients with non-squamous tumors in the Phase IIb portion of the double-blind, international Phase IIb/III TIME trial showed that first-line treatment with subcutaneous TG4010 plus chemotherapy significantly improved median PFS (5.8 vs. 5 months, p=0.0093) and the 9-month PFS rate (35% vs. 19%) vs. placebo plus chemotherapy. In the subgroup, TG4010 also significantly improved median OS (14.6 vs. 10.8, p=0.494) and the 18-month OS rate (40% vs. 34%) vs. placebo. In a subgroup of 127 patients with non-squamous tumors and low levels of triple-positive activated lymphocytes (CD16+, CD56+ and CD69+ lymphocytes), TG4010 significantly improved median PFS (6 vs. 4.9 months, p=0.0033); the 9-month PFS rate (39% vs. 19%); median OS (15.2 vs. 10.3 months, p=0.0188); and the 18-month OS rate (44% vs. 30%) vs. placebo. ...